National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Olaparib monotherapy is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 30/04/2019
Rapid review completed 09/05/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 15/05/2019
Pre-submission consultation with Applicant 15/07/2019
Submission received from Applicant 10/10/2019
Preliminary review sent to Applicant 08/01/2020
NCPE assessment re-commenced 24/01/2020
Factual accuracy sent to Applicant 09/03/2020
NCPE assessment re-commenced 13/03/2020
NCPE assessment completed 30/03/2020
NCPE assessment outcome Following assessment of the Applicant’s submission, the NCPE recommends that olaparib (Lynparza®) for this indication not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.